Pacira Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 2, 2015, details the results of Pacira Pharmaceuticals, Inc.'s 2015 Annual Meeting of Stockholders held at its headquarters in Parsippany, New Jersey.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders approved three proposals at the annual meeting:
- Proposal 1 (Election of Directors): Three Class I directors were elected to serve until the 2018 Annual Meeting.
- Laura Brege: 25,148,577 For; 2,703,160 Withheld.
- Mark A. Kronenfeld: 26,686,306 For; 1,165,431 Withheld.
- Dennis L. Winger: 27,763,019 For; 88,718 Withheld.
- Proposal 2 (Auditor Ratification): Ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2015.
- For: 33,054,850; Against: 41,601; Abstain: 25,892.
- Proposal 3 (Executive Compensation): Advisory vote to approve the compensation of named executive officers.
- For: 27,579,771; Against: 214,828; Abstain: 57,138.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the tenure of the newly elected Class I directors (Laura Brege, Mark A. Kronenfeld, Dennis L. Winger) through the 2018 Annual Meeting.
- Confirm the engagement of CohnReznick LLP as the independent auditor for the fiscal year ending December 31, 2015.
- Note the significant number of Broker Non-Votes (5,270,606) recorded for the director election and executive compensation proposals.